Supportive care in elderly cancer patients

Current Opinion in Oncology

Volumn 21, Issue 4, 2009, Pages 310-317

  Balducci, Lodovico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Chemotherapy; Elderly; Older patients; Supportive care; Systemic treatment

Indexed keywords

ALKALOID; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICINOL; DOXORUBICIN; EPOTHILONE DERIVATIVE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; GONADORELIN DERIVATIVE; IDARUBICINOL; KERATINOCYTE GROWTH FACTOR; METHOTREXATE; NAVELBINE; PEMETREXED; PLATINUM DERIVATIVE; PREDNISOLONE; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

AGING; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; ELDERLY CARE; GROUPS BY AGE; HUMAN; NEOPLASM; NEUTROPENIA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; AGE; AGED; GERIATRIC ASSESSMENT; METHODOLOGY; PALLIATIVE THERAPY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; GERIATRIC ASSESSMENT; HUMANS; NEOPLASMS; PALLIATIVE CARE;

EID: 67650315454     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832b4f25     Document Type: Review

References (81)

1. Balducci L, Ershler WB. Cancer and ageing: a nexus at several levels. Nat Rev Cancer 2005; 5:655-662.
2. Yancik R. Population aging and cancer: a cross national problem. Cancer J 2005; 11:437-441.
3. Walston J, Hadley EC, Ferrucci L, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006; 54:991 -1001.
4. Kaushansky K. Lineage specific hematopoietic growth factors. N Engl J Med 2006; 354:2034-2045.
5. ViJg J, Campisi J. Puzzles, promises and a cure for ageing. Nature 2008; 454:1065-1071.
6. Campisi J. Senescent cells, tumor suppression and organizational aging: good citizens, bad neighbors. Cell 2005; 120:513-522.
7. Campisi J, dAdda di Fagnana F. Cellular senescence: when bad things happen to good cells. Nat Rev 2007; 8:729-740.
8. Ferrucci L, Corsi A, Lauretani F, et al. The origin of age-related pro-inflammatory state. Blood 2005; 105:2294-2299.
9. Stein PK, Barzilay JI, Chaves PH, et al. Higher levels of inflammation factors and higher insulin resistance are independently associated with higher heart rate and lower heart rate variability in normoglycemic older men. J Am Geriatr Soc 2008; 56:315-321.
10. Gurven M, Kaplan H, Winking J, et al. Aging and inflammation in two epidemiological worlds. J Gerontol A Biol Sci Med Sci 2008; 63:196-199. Important review of the interactions of inflammation and aging.
11. Crimmins E, Vasunilashorn S, Kim JK, Alley D. Biomarkers related to aging in the human population. Adv Clin Chem 2008; 46:161 -216.
12. Maggio M, Guralnik JM, Longo DL, Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci 2006; 61:575-584.
13. Cohen HJ, Harris T, Pieper CF. Coagulation and activation of inflammatory pathwaysin the developmentoffunctional decline and mortalityin theelderly. Am J Med 2003; 114:180-187.
14. Extermann M, HurriaA.comprehensivegeriatric assessmentin older patients with cancer. J Clin Oncol 2007; 25:1824-1831.
15. Barbotte E, Guillemin F, Chaun N, et al. Prevalenceofimpairments, disabilities and handicaps and quality of life of the general population: a review of recent literature. Bull World Health Organ 2001; 79:1047-1055.
16. Stork S, Feelder RA, Van der Beld AW, et al. Prediction ofmortalityrisk in the elderly. Am J Med 2006; 119:519-525.
17. Carey EC, Covinsky KE, Lui LY, et al. Prediction of mortality in community- living frail elderly people with long-term care needs. J Am Geriatr Soc 2008; 56:68-75.
18. Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006; 295: 801 -808.
19. Extermann M, Chen A, Cantor AB, et al. Predictorsoftolerance ofchemother- apy in older patients. Eur J Cancer 2002; 38:1466-1473.
20. Kulminsky AM, Ukraintseva SV, Kulminskaya AV, et al. Cumulative deficits better characterizes susceptibility to death in elderly people than phenotypic frailty. Lessons from the Cardiovascular Health Study. J Am Geriatr Soc 2006; 56:898-903.
21. Extermann M. Interactions of cancer and comorbidity. Cancer Control 2007; 14:13-22.
22. Barone BB, Yeh C, Snyder CF, et al. Long term all cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300:2754-2764.
23. Kaklamani VG, Wisinski KB, Sadim M, et al. Variants of adiponectin and adiponectin receptor 1 genes and colorectal cancer. JAMA 2008; 300: 1523-1531.
24. Anisov VN. Biology of aging and cancer. Cancer Control 2007; 14:23-31.
25. Ferucci L, Balducci L. Anemia of aging: role of chronic inflammation and cancer. Semin Hematol 2008; 45:242-249.
26. GualnikJM, EisnestaedtRS, Ferrucci L, et al. Prevalenceofanemiain persons 65 year and older in the United States: evidence for a high rate ofunexplained anemia. Blood 2004; 104:2263-2268.
27. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26:132-149.
28. Bohlius J, Enget A, Schwarzer G. Erythropoiesis stimulating agents in cancer associated anemia. JAMA 2008; 300:2854-2855.
29. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thrombo-embolism and mortality associated with recombinant erythropoietin and darbepoetin administration in the treatment of cancer associated anemia. JAMA 2008; 299:914-924.
30. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results ofthe BreastCancer-Anemiaand the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008; 26:592-598.
31. Heider SI, Johnell K, Weitoft GI, et al. The influence of educational level on polypharmacy and inappropriate drug use. A register based study of more than 600000 older people. J Am Geriatr Soc 2009; 57:62-69.
32. Inouye SK, Studenski B, Timetti ME, et al. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 2007; 55:780-791.
33. Hshieh TT, Fong TG, Marcantonio ER, et al. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci 2008; 63:764-772.
34. Tinetti ME, Gordon C, Sogolow E, et al. Fall-risk evaluation and management: challenges in adopting geriatric care practices. Gerontologist 2006; 46:717-725.
35. Rhee YS, Yun YH, Parks S, et al. Depression in family caregivers of cancer patients: the feeling of burden as a predictor of depression. J Clin Oncol 2008; 36:5890-5895.
36. Haley WE. The cost of family caregiving: implications for geriatric oncology. Crit Rev Oncol Hematol 2003; 48:151-158.
37. Balducci L, Cohen HJ, Engstrom P, et al. Senior adult oncology clinical practice guidelines in oncology. J Natl Compr Canc Netw2005; 3:572-590.
38. Extermann M, Overcash J, Lyman GH, et al.comorbidity and performance status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
39. Repetto L, Fratino L, Audisio R, et al.comprehensive geriatric assessment adds information to Eastern Cooperative Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 15:494-502.
40. Ingram SS, Seo PH, Martell RE, et al.comprehensive assessment of elderly cancer patients: the feasibility of self-report methodology. J Clin Oncol 2002; 20:770-775.
41. Fried LP, Tangen CM, Wakston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-M156.
42. Anonymous. Assessing care of vulnerable elders: 3 quality indicators. J Am Geriatr Soc 2007; 55 (Suppl 2):s464-s487.
43. Xue QL, Bandeen-Roche K, Varadhan R, et al. Initial manifestations of frailty criteria and the development of frailty phenotype in the Women Health and Aging Study II. J Gerontol A Biol Sci Med Sci 2008; 63:984-990.
44. Katz S, Branch LB, Branson MH, et al. Active life expectancy. N Engl J Med 1983; 309:1218 -1224.
45. Jagger C, Matthews R, Matthews F, et al. The burden of diseases on disability- free life expectancy in later life. J Gerontol A Biol Sci Med Sci 2007; 62:408-414.
46. Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalisation for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 2006; 17:647 -654.
47. Luciani A, Jacobsen PB, Extermann M, et al. Fatigue and functional dependence in older cancer patients. Am J Clin Oncol 2008; 31:424-430.
48. Vestergaard S, Nayfield SG, Patel KV, et al. Fatigue in a representative population of older persons and its association with functional impairment, functional limitations and disability. J Gerontol A Biol Sci Med Sci 2009; 64:76-82.
49. Hardy SE, Studenski SA. Fatigue and function over 3 years among older adults. J Gerontol A Biol Sci Med Sci 2008; 63:1389-1392.
50. Hardy SE, Studenski SA. Fatigue predicts mortality in older adults. J Am Geriatr Soc 2008; 56:1910-1914.
51. Perkins EA, Small BJ, Balducci L, et al. Individual differences in well being in older breast cancer survivors. Crit Rev Oncol Hematol 2007; 62:74-83.
52. Robb C, Haley WE, Balducci L, et al. Impact of breast cancer survivorship on quality of life in older patients. Crit Rev Oncol Hematol 2007; 62:84-91.
53. Balducci L. Cancer chemotherapy in the older person. In: Balducci L, Ershler WB, DeGaetano G, editors. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008. The most recent review of the administration of cytotoxic chemotherapy to older cancer patients.
54. Balducci L. Cancer chemotherapy in the older patient. Oncology 2009; 23:78-85.
55. Schrijvers D, Highley M, DeBruyn E, et al. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 1999; 10:147 -153.
56. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulas in estimating renal function in elderly cancer patients. Ann Oncol 2004; 15:291-295.
57. Melchert M, Lancet J. Acute myeloid leukemia in the elderly. In: Balducci L, Erhsler WB, DeGaetano G, editors. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008. pp. 237-255.
58. Vitolo U, Ferreri AJ, Montoto S. Follicular lymphomas. Crit Rev Oncol Hematol 2008; 66:248-261.
59. Daidone MG, Coradini D, Martelli G, et al. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 2003; 45:313-325.
60. Balducci L, Hardy CL. Hematopoietic reserve and aging. In: Balducci L, Ershler WB, DeGaetano G, editors. Blood disorders in the elderly. Cambridge: Cambridge University Press; 2008.
61. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25:3158-3167.
62. Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hemato- logic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007; 110:1611 -1620.
63. Balducci L, Al Halawani H, Charu V, et al. Elderly patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007; 12:1416-1424.
64. Smith TJ, Katcheressian J, Lyman GH, et al. 2006 update ofrecommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187-3205.
65. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 2007; 5 (9 Suppl 4):3-11.
66. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorour- acil-based chemotherapy. J Clin Oncol 2006; 24:5194-5200.
67. Broder H, Gottlieb RA, Lepor NE. Chemotherapy and cardiotoxicity. Rev Cardiovasc Med 2008; 9:75-83.
68. Ewer SM, Ewer MS. Cardiotoxic profile of trastuzumab. Drug Saf 2008; 31:459 -467.
69. Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity ofcancer therapy. J Clin Oncol 2005; 23:7685-7696; review.
70. Walker M, Ni O. Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol 2007; 30:82 -92.
71. Ramalingam SS, Dalberg SE, Langer CS, et al. Outcomes for elderly non small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26:60-65.
72. Kohne CH, Folprecth G, Golberg AM, et al. Chemotherapy in elderly patients with colorectal cancer. Oncologist 2008; 13:390-402.
73. Schaapveld M, Visser O, Lowman MJ, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 2008; 26:1239-1246.
74. Muss HB, Berry DA, Cirrincione C, et al. Toxicityofolder and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 2007; 25:3699-3704.
75. Patt DA, Duan Z, Fang S, et al. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2007; 25:3871 -3876.
76. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breastcancer adjuvantchemotherapy. J Natl Cancer Inst2007; 99:196 -205.
77. Pinder M, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 2007; 25:3808-3815.
78. Herhman DL, McBride RB, Eisenberger R, et al. Doxorubicin, cardiac risk factors and cardiac toxicityin elderlypatients with diffuse B cell non Hodgkin's lymphoma. J Clin Oncol 2008; 26:3159 -3165.
79. Heck JE, Albert SM, Franco R, Gorin SS. Pattern of dementia diagnosis in surveillance, epidemiology and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc 2008; 56:1687 -1692.
80. Shainian VB, Kuo YE, Freeman JL, et al. Risk of bone fracture after androgen deprivation in prostate cancer. N Engl J med 2005; 352:154-164.
81. Leahy Y. Risk of metabolic syndrome, cardiovascular diseases and diabetes in androgen deprivation therapy. Clin J Oncol Nurs 2008; 12:771-776.